Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the acquisition of GSK Ordinary Shares by specific executives on June 9, 2015, at a price of 1378.53 pence per share through the GSK ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the mechanics of the share acquisition plan.
Important Facts for Investors
- Transaction Date: Shares were acquired on June 9, 2015.
- Share Price: 1378.53 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Acquisition Structure: Shares were acquired via the ShareReward Plan, consisting of both personal contribution and matching GSK contribution elements.
- Volume: Most participants acquired 10 shares under each element; Mr N Hirons, Mr P C Thomson, and Dr P J T Vallance acquired 9 shares under each element.